-
Published 8/11/2026
Azzam M, Hamarsha Q, Kawtharany H, Nazzal J, Alkhader A, Khraise T, AlMasri MM, Abou Zeid HK, Alwan I, Jaber N, Seftel MD, Aguirre MA, Boedicker D, Bumma N, Carroll A, Comenzo R, Cook J, Dasgupta N, De La Torre AH, Dispenzieri A, Jamal F, Khouri J, Picken MM, Raza S, Leung N, Sanchorawala V, Sarswat N, Shaikh H, Singh D, Kukreti V, Mustafa RA. Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis. Blood Adv. 2026 Aug 11; 10(15):5293-5307. PMID: 41979328.
-
Published 8/3/2026
Wechalekar AD, Dispenzieri A, Sanchorawala V, Kastritis E, Bhutani D, Bianchi G, Jimenez-Zepeda VH, Suzuki K, Lentzsch S, Huart A, Carpinteiro A, Swenson ES, Khan Z, Catini J, Kulkarni H, Meltzer B, Lake S, Liedtke M. Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. J Clin Oncol. 2026 Aug 03; JCO2601665. PMID: 42546230.
-
Published 7/28/2026
Kukreti V, Seftel M, Aguirre MA, Azzam M, Boedicker DD, Bumma N, Carroll AS, Comenzo R, Cook J, Dasgupta N, De La Torre A, Dispenzieri A, Jamal F, Kawtharany H, Khouri J, Leung N, Nazzal J, Picken MM, Raza S, Sanchorawala V, Sarswat N, Shaikh H, Singh D, Mustafa RA. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Blood Adv. 2026 Jul 28; 10(14):5113-5152. PMID: 41592868.
-
Published 7/20/2026
Alqazaqi R, Taasan S, Schwartzman W, Khan AM, Afrough A, Zahid MF, Schinke C, van Rhee F, Anderson LD, Sanchorawala V, Al Hadidi S. Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis. Blood Adv. 2026 Jul 20. PMID: 42478693.
-
Published 7/14/2026
Berumen A, Staron A, Kalaitzidis G, Siddiqi OK, Gopal DM, Ruberg FL, Sanchorawala V. Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era. Blood Adv. 2026 Jul 14; 10(13):4612-4616. PMID: 41995749.